Matches in SemOpenAlex for { <https://semopenalex.org/work/W3035021230> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W3035021230 endingPage "418" @default.
- W3035021230 startingPage "415" @default.
- W3035021230 abstract "Apremilast is a phosphodiesterase-4 inhibitor taken orally. Little information about its use in routine clinical practice is available. We aimed to assess treatment safety and persistence rates in patients on apremilast for different forms of plaque psoriasis. This observational retrospective study included 30 patients with psoriasis who were treated with apremilast between January 2016 and December 2017 in our hospital. Twelve patients had palmar-plantar psoriasis, 8 had plaque psoriasis mainly on the scalp, and 10 had plaque psoriasis in other locations. The probable period of treatment persistence in patients in the 50th percentile was 18.5 months according to survival analysis of the series overall. Our experience suggests that apremilast is effective and safe for treating palmar-plantar psoriasis and plaques at other locations but not for treating scalp psoriasis. Adverse effects that compromise treatment occur in nearly two-thirds of the patients. El apremilast es un inhibidor vía oral de la fosfodiesterasa-4 con pocos datos de práctica clínica habitual. Nuestro objetivo fue evaluar la persistencia y la seguridad del apremilast en la práctica clínica en distintas formas clínicas de psoriasis. Se realizó un estudio observacional retrospectivo de los 30 pacientes con psoriasis que recibieron el fármaco entre enero de 2016 y diciembre de 2017 en nuestro centro, 10 con psoriasis en placas, 8 con placas predominantemente en el cuero cabelludo y 12 palmo-plantares. El tiempo global de probabilidad de supervivencia del 50% fue de 18,5 meses. En nuestra experiencia, el apremilast es un fármaco efectivo y seguro para la psoriasis en placas y palmo-plantar, no así para la afectación del cuero cabelludo. Los efectos secundarios ocurren en casi dos tercios de los pacientes comprometiendo la persistencia del tratamiento." @default.
- W3035021230 created "2020-06-19" @default.
- W3035021230 creator A5002256998 @default.
- W3035021230 creator A5006811851 @default.
- W3035021230 creator A5013187605 @default.
- W3035021230 creator A5013396852 @default.
- W3035021230 creator A5051279719 @default.
- W3035021230 date "2020-06-01" @default.
- W3035021230 modified "2023-10-16" @default.
- W3035021230 title "Treatment Persistence and Safety of Apremilast in Psoriasis: Experience With 30 Patients in Routine Clinical Practice" @default.
- W3035021230 cites W1587903002 @default.
- W3035021230 cites W1919283206 @default.
- W3035021230 cites W1965589159 @default.
- W3035021230 cites W2005891936 @default.
- W3035021230 cites W2101175089 @default.
- W3035021230 cites W2131727392 @default.
- W3035021230 cites W2190836745 @default.
- W3035021230 cites W2193061610 @default.
- W3035021230 cites W2304028829 @default.
- W3035021230 cites W2755210722 @default.
- W3035021230 doi "https://doi.org/10.1016/j.adengl.2018.10.035" @default.
- W3035021230 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32423533" @default.
- W3035021230 hasPublicationYear "2020" @default.
- W3035021230 type Work @default.
- W3035021230 sameAs 3035021230 @default.
- W3035021230 citedByCount "2" @default.
- W3035021230 countsByYear W30350212302022 @default.
- W3035021230 crossrefType "journal-article" @default.
- W3035021230 hasAuthorship W3035021230A5002256998 @default.
- W3035021230 hasAuthorship W3035021230A5006811851 @default.
- W3035021230 hasAuthorship W3035021230A5013187605 @default.
- W3035021230 hasAuthorship W3035021230A5013396852 @default.
- W3035021230 hasAuthorship W3035021230A5051279719 @default.
- W3035021230 hasBestOaLocation W30350212301 @default.
- W3035021230 hasConcept C126322002 @default.
- W3035021230 hasConcept C16005928 @default.
- W3035021230 hasConcept C197934379 @default.
- W3035021230 hasConcept C23131810 @default.
- W3035021230 hasConcept C2776260265 @default.
- W3035021230 hasConcept C2780564577 @default.
- W3035021230 hasConcept C2781427535 @default.
- W3035021230 hasConcept C3020604521 @default.
- W3035021230 hasConcept C71924100 @default.
- W3035021230 hasConceptScore W3035021230C126322002 @default.
- W3035021230 hasConceptScore W3035021230C16005928 @default.
- W3035021230 hasConceptScore W3035021230C197934379 @default.
- W3035021230 hasConceptScore W3035021230C23131810 @default.
- W3035021230 hasConceptScore W3035021230C2776260265 @default.
- W3035021230 hasConceptScore W3035021230C2780564577 @default.
- W3035021230 hasConceptScore W3035021230C2781427535 @default.
- W3035021230 hasConceptScore W3035021230C3020604521 @default.
- W3035021230 hasConceptScore W3035021230C71924100 @default.
- W3035021230 hasIssue "5" @default.
- W3035021230 hasLocation W30350212301 @default.
- W3035021230 hasOpenAccess W3035021230 @default.
- W3035021230 hasPrimaryLocation W30350212301 @default.
- W3035021230 hasRelatedWork W2083656392 @default.
- W3035021230 hasRelatedWork W2398457950 @default.
- W3035021230 hasRelatedWork W2904182792 @default.
- W3035021230 hasRelatedWork W2955438334 @default.
- W3035021230 hasRelatedWork W2972259840 @default.
- W3035021230 hasRelatedWork W2981869923 @default.
- W3035021230 hasRelatedWork W2993521953 @default.
- W3035021230 hasRelatedWork W3108657795 @default.
- W3035021230 hasRelatedWork W3195838575 @default.
- W3035021230 hasRelatedWork W4284703618 @default.
- W3035021230 hasVolume "111" @default.
- W3035021230 isParatext "false" @default.
- W3035021230 isRetracted "false" @default.
- W3035021230 magId "3035021230" @default.
- W3035021230 workType "article" @default.